Immunocore

Immunocore announces clinical trial collaboration and supply agreement with Bristol Myers Squibb to evaluate IMC-F106C (PRAME HLA-A02) in combination with nivolumab in its registrational Phase 3 first-line advanced cutaneous melanoma trial

Retrieved on: 
Thursday, February 22, 2024
BMY, Nivolumab, Bristol Myers Squibb, PRAME, Patient, Clinical trial, TCR, Infection, Immunocore, Relatlimab, Cancer, Pharmaceutical industry

IMC-F106C is Immunocore’s first-in-class bispecific TCR ImmTAC candidate targeting PRAME HLA-A02; nivolumab is manufactured by Bristol Myers Squibb

Key Points: 
  • IMC-F106C is Immunocore’s first-in-class bispecific TCR ImmTAC candidate targeting PRAME HLA-A02; nivolumab is manufactured by Bristol Myers Squibb
    The clinical trial collaboration relates to Immunocore’s PRISM-MEL-301 registrational Phase 3 clinical trial in first-line advanced cutaneous melanoma, evaluating IMC-F106C in combination with nivolumab versus a control arm of either nivolumab or the fixed-dose combination of nivolumab and relatlimab
    (OXFORDSHIRE, England & CONSHOHOCKEN, Penn.
  • Under the terms of the collaboration, Immunocore will sponsor and fund the registrational Phase 3 clinical trial of IMC-F106C in combination with nivolumab in first-line advanced cutaneous melanoma (PRISM-MEL-301), and Bristol Myers Squibb will provide nivolumab.
  • The PRISM-MEL-301 trial will randomize HLA-A*02:01+ first-line advanced cutaneous melanoma patients to IMC-F106C + nivolumab versus a control arm of either nivolumab or the fixed-dose combination of nivolumab and relatlimab, depending on the country where the patient is enrolled.
  • Immunocore plans to randomize the first patient in this trial in the first quarter of 2024.

DELFI Diagnostics Announces Availability of New Fragmentome-Based Cancer Treatment Monitoring Assay

Retrieved on: 
Thursday, February 1, 2024
Liquid biopsy, MAF, Immunocore, Research, Clonal hematopoiesis, PALO, Patient, DELFI, TCR, ImmTAC, RUO, Neoplasm, Cancer, Plasma, Nucleic acid thermodynamics

PALO ALTO, Calif. and BALTIMORE, Feb. 1, 2024 /PRNewswire/ -- DELFI Diagnostics, Inc., a developer of accessible blood-based tests that deliver a new way to enhance cancer detection, today announced availability of the company's fragmentome-based research use only (RUO) cancer monitoring assay. The DELFI-Tumor Fraction (DELFI-TF) assay is a highly sensitive, inexpensive means of noninvasive measurement of tumor burden and assessing treatment response and resistance in patients with advanced cancer.

Key Points: 
  • PALO ALTO, Calif. and BALTIMORE, Feb. 1, 2024 /PRNewswire/ -- DELFI Diagnostics, Inc., a developer of accessible blood-based tests that deliver a new way to enhance cancer detection, today announced availability of the company's fragmentome-based research use only (RUO) cancer monitoring assay.
  • The DELFI-Tumor Fraction (DELFI-TF) assay is a highly sensitive, inexpensive means of noninvasive measurement of tumor burden and assessing treatment response and resistance in patients with advanced cancer.
  • Additionally, DELFI announced a new research collaboration with Immunocore Holdings plc (Nasdaq: IMCR) – a commercial-stage biotechnology company pioneering the development of a novel class of bispecific T cell receptor (TCR) immunotherapies against cancer (ImmTAC molecules) – focused on exploring the use of the DELFI-TF cancer monitoring assay as an early predictor of benefit from treatment with ImmTAC-based therapies.
  • "We are excited that Immunocore will be further exploring the clinical and research potential of the DELFI liquid biopsy platform as a new approach to monitoring treatment response."

Industry Veteran Abbas Hussain Appointed as Chair of Asceneuron

Retrieved on: 
Monday, December 18, 2023
SAN, Chair, Teva Pharmaceuticals, Abingworth (company), Patient, Adviser, Sofinnova, Spondyloarthropathy, Medicinal chemistry, Capital, CSL Limited, Stanford University, Eli Lilly, Pamlab, Conference, CSL Vifor, Non-executive director, Growth, GSK plc, OGA, Cochlear Limited, Pharmaceutical industry, Science, Immunocore

Abbas Hussain has over 35 years of experience in the healthcare industry, building and growing businesses across the globe.

Key Points: 
  • Abbas Hussain has over 35 years of experience in the healthcare industry, building and growing businesses across the globe.
  • Abbas Hussain, Chair of the Board of Directors of Asceneuron, remarked: "There have been tremendous advances in the treatment of neurodegenerative disorders which impact millions of people globally every year.
  • Abbas currently holds various Non-Executive Director and Advisor roles at Alfasigma SpA, 4Bio Capital, C-Bridge Capital and GLG Institute.
  • In addition, Abbas also provides expert advisory services to private equity and venture capital firms focused on the healthcare sector.

Industry Veteran Abbas Hussain Appointed as Chair of Asceneuron

Retrieved on: 
Monday, December 18, 2023
SAN, Chair, Teva Pharmaceuticals, Abingworth (company), Patient, Adviser, Sofinnova, Spondyloarthropathy, Medicinal chemistry, Capital, CSL Limited, Stanford University, Eli Lilly, Pamlab, Conference, CSL Vifor, Non-executive director, Growth, GSK plc, OGA, Cochlear Limited, Pharmaceutical industry, Science, Immunocore

Abbas Hussain has over 35 years of experience in the healthcare industry, building and growing businesses across the globe.

Key Points: 
  • Abbas Hussain has over 35 years of experience in the healthcare industry, building and growing businesses across the globe.
  • Abbas Hussain, Chair of the Board of Directors of Asceneuron, remarked: "There have been tremendous advances in the treatment of neurodegenerative disorders which impact millions of people globally every year.
  • Abbas currently holds various Non-Executive Director and Advisor roles at Alfasigma SpA, 4Bio Capital, C-Bridge Capital and GLG Institute.
  • In addition, Abbas also provides expert advisory services to private equity and venture capital firms focused on the healthcare sector.

Dr. Jinzi J. Wu Presents at the 10th International Workshop on HBV Cure 2023

Retrieved on: 
Thursday, November 9, 2023
Massachusetts General Hospital, Patient, HKEX, Research, PD-L1, Hepatitis B virus, Trial of the century, Harvard Medical School, AIDS, National Institutes of Health, Lim, Johns Hopkins University, Arbutus, Prevalence, Jacob Aligo, Safety, PD-1, University of Milan, CHB, University of Hong Kong, Virus, Phase, Immunotherapy, Risk, HIV/AIDS research, International Workshop on Lung Health, Bangladesh Technical Education Board, GSK, University, Roche, HBsAg, VIR, University of Oxford, Toronto Centre, Liver disease, HBV, Hook effect, Village Vanguard Live Sessions 3, Vaccine, Pharmaceutical industry, Northwestern University, Immunocore

HANGZHOU and SHAOXING, China, Nov. 8, 2023 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") today announces that Dr. Jinzi J. Wu, Founder, Chairman and CEO of Ascletis was invited to attend and have a presentation at the 10th International Workshop on HBV Cure 2023 held at Boston, United States.

Key Points: 
  • HANGZHOU and SHAOXING, China, Nov. 8, 2023 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") today announces that Dr. Jinzi J. Wu, Founder, Chairman and CEO of Ascletis was invited to attend and have a presentation at the 10th International Workshop on HBV Cure 2023 held at Boston, United States.
  • The interim analysis included 25 patients who completed 24-week treatment (19 patients in ASC22 cohort and 6 patients in placebo cohort).
  • Topline results indicated that in ASC22 cohort, 4 patients (4/19, 21.1%) achieved HBsAg loss at the end of 24-week treatment.
  • "It's a great honor to be invited to the 10th International Workshop on HBV Cure 2023 and share our latest progress in developing the immune checkpoint inhibitor for functional cure of CHB with the global industry.

Immunocore Reports Third Quarter 2023 Financial Results and Provides Business Update

Retrieved on: 
Tuesday, November 7, 2023
Research, European Organisation for Research and Treatment of Cancer, Treatment, Ipilimumab, Record, Melanoma, Viral load, OS, Neoplasm, PIWIL1, BRAF, Sale, ESMO, EORTC, HIV, Circulating tumor DNA, World Games, The New England Journal of Medicine, Cancer, Patient, DNA, Nivolumab, Congress, CTA, MAD, Insming, Oncology, RFS, PRAME, Nivolumab/relatlimab, TCR International, European Society of Gynaecological Oncology, IND, SVP, TCR, Gastrointestinal cancer, European Society for Medical Oncology, Observation, Senior, Infection, Book, James A. Schlipmann Melanoma Cancer Foundation, HBV, Pharmaceutical industry, Cryptocurrency, Medical imaging, USD, IMC, Immunocore

& ROCKVILLE, Md., US, 07 November 2023) Immunocore Holdings plc (Nasdaq: IMCR), a commercial-stage biotechnology company pioneering the development of a novel class of T cell receptor (TCR) bispecific immunotherapies designed to treat a broad range of diseases, including cancer, infectious diseases and autoimmune conditions, today announced its financial results for the third quarter ended September 30, 2023, and provided a business update.

Key Points: 
  • & ROCKVILLE, Md., US, 07 November 2023) Immunocore Holdings plc (Nasdaq: IMCR), a commercial-stage biotechnology company pioneering the development of a novel class of T cell receptor (TCR) bispecific immunotherapies designed to treat a broad range of diseases, including cancer, infectious diseases and autoimmune conditions, today announced its financial results for the third quarter ended September 30, 2023, and provided a business update.
  • Commercial sales have increased in the United States and European countries, including France, Germany and Italy, during the third quarter.
  • Since the beginning of 2023, we have launched KIMMTRAK in Austria, Israel, Italy, Finland, Switzerland and Belgium, and have recently reached price agreements with Canada and Australia.
  • Cash and cash equivalents were £364.0 million ($444.5 million) as of September 30, 2023, compared to £332.5 million as of December 31, 2022.

Immunocore presents three-year overall survival data from the KIMMTRAK Phase 3 trial

Retrieved on: 
Saturday, October 21, 2023
Survival, Aes, ESMO, TCR, Congress, European Society for Medical Oncology, Mum, Melanoma, The New England Journal of Medicine, Oncology, Infection, Safety, Cancer, Immunocore, Patient, OS, Neoplasm, DNA, BRAF, Pharmaceutical industry

“These long-term overall survival results further solidify KIMMTRAK as the first-line standard of care for HLA-A*02:01 positive patients with metastatic uveal melanoma,” said Mohammed Dar, Immunocore Chief Medical Officer.

Key Points: 
  • “These long-term overall survival results further solidify KIMMTRAK as the first-line standard of care for HLA-A*02:01 positive patients with metastatic uveal melanoma,” said Mohammed Dar, Immunocore Chief Medical Officer.
  • Overall response rate remained in favor of KIMMTRAK when compared with the control arm (11% vs 5%) and the median duration of response for KIMMTRAK patients was 11.1 months.
  • The trial evaluated circulating tumor DNA (ctDNA) clearance as a predictor of overall survival.
  • Session: Mini oral session – Melanoma and other skin tumours, Saturday 21 October, 2023
    Title: Effect of subsequent therapies including checkpoint inhibitors on overall survival in a phase 3 randomized trial of tebentafusp in first line metastatic uveal melanoma: long-term follow up

Ion Channel Drug Developer Maxion Therapeutics Appoints Eva-Lotta Allan as Chair of its Board of Directors

Retrieved on: 
Thursday, September 21, 2023
Partnership, G protein-coupled receptor, Iochpe-Maxion, Biotechnology, Roger W. Jones Award for Executive Leadership, Almirall, Antibody, USD, BGF, NED, Immunocore, GPCR, Partner, Patient, CBO, Chairperson, Drug discovery, Growth, Ablynx, Therapy, Eva-Lotta Kiibus, Chronic pain, Eurosport 1, Nomination, Management

Eva-Lotta Allan, Chair, Board of Directors, Maxion Therapeutics, commented: "I'm delighted to be appointed to Maxion at such an exciting time in its development.

Key Points: 
  • Eva-Lotta Allan, Chair, Board of Directors, Maxion Therapeutics, commented: "I'm delighted to be appointed to Maxion at such an exciting time in its development.
  • I look forward to working with the Board of Directors and the rest of the Maxion team to help improve patients' lives while creating value for our shareholders."
  • KnotBody technology combines the benefits of naturally occurring mini-proteins, which have ion channel modulating activity, with antibodies, using state-of-the-art phage and mammalian display technologies.
  • The resulting fusion protein, which combines the drug-like benefits of both molecules, helps address key challenges in ion channel and GPCR drug discovery.

National Cancer Institute (NCI) Director, Monica M. Bertagnolli, M.D., Selected as Recipient of the 2023 AIM-HI Beacon Award for Women Leaders in Oncology

Retrieved on: 
Wednesday, August 16, 2023
Research, Women, Public Policy, Government, Philanthropy, White House, Federal Government, Consumer, Health, Foundation, Science, Oncology, National Foundation for Cancer Research, Survivor, Entrepreneurship, Drug development, University, Therapy, Women Leaders in Global Health Conference, Gastrointestinal cancer, AoC Beacon Awards, National Press Club (United States), Cancer, Quality of life, Biomedical Research, Press club, Woman, University of California, San Diego, Harvard Medical School, National Cancer Institute, Surgical oncology, Patient, Arizona State University, Bertagnolli, Diagnosis, NFCR, Director of the National Institutes of Health, Empathy, Complex adaptive system, NCI, NIH, Dana–Farber Cancer Institute, Pharmaceutical industry, Nursing, Management, Immunocore, Brigham

The AIM-HI Accelerator Fund (AIM-HI) today announced the recipient of the 2023 AIM-HI Beacon Award for Women Leaders in Oncology as Monica M. Bertagnolli, M.D., Director of the National Cancer Institute (NCI) .

Key Points: 
  • The AIM-HI Accelerator Fund (AIM-HI) today announced the recipient of the 2023 AIM-HI Beacon Award for Women Leaders in Oncology as Monica M. Bertagnolli, M.D., Director of the National Cancer Institute (NCI) .
  • The Beacon Award for Women Leaders in Oncology was established in 2022 by the AIM-HI Accelerator Fund, a translational research and impact-investment affiliate of the National Foundation for Cancer Research (NFCR).
  • Dr. Bertagnolli will be honored as the 2023 AIM-HI Beacon Award recipient at a luncheon ceremony at the National Press Club in Washington, D.C., on October 21, 2023.
  • Tickets to attend the 2023 Global Summit and Award Ceremonies for Cancer Research and Entrepreneurship are now open for purchase.

Immunocore to report second quarter 2023 financial results and host call on August 10, 2023

Retrieved on: 
Thursday, August 3, 2023
Cancer, Infection, EDT, TCR, Webcast, BST, Vaccine, Immunocore

Immunocore to report second quarter 2023 financial results and host call on August 10, 2023

Key Points: 
  • Immunocore to report second quarter 2023 financial results and host call on August 10, 2023
    (OXFORDSHIRE, England & CONSHOHOCKEN, Penn.
  • & ROCKVILLE, Md., US, 03 August 2023) Immunocore Holdings Plc (Nasdaq: IMCR), a commercial-stage biotechnology company pioneering the development of a novel class of T cell receptor (TCR) bispecific immunotherapies designed to treat a broad range of diseases, including cancer, infectious diseases and autoimmune conditions, today announced that it will report second quarter financial results, before the US markets open on Thursday, August 10, 2023.
  • Following the announcement, the Company will host a live teleconference and webcast at 8:00 a.m. EDT (1:00 p.m. BST) to discuss their financial results and provide a business and portfolio update.
  • The call will be webcast live and can be accessed by visiting ‘Events’, under ‘News & Events’, via the ‘Investors’ section of Immunocore’s website at www.immunocore.com.